Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study
Published 2021 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
Safety, reactogenicity, and immunogenicity of homologous and heterologous prime-boost immunisation with ChAdOx1 nCoV-19 and BNT162b2: a prospective cohort study
Authors
Keywords
-
Journal
Lancet Respiratory Medicine
Volume -, Issue -, Pages -
Publisher
Elsevier BV
Online
2021-08-13
DOI
10.1016/s2213-2600(21)00357-x
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Could mixing COVID vaccines boost immune response?
- (2021) Heidi Ledford NATURE
- BNT162b2 mRNA Covid-19 Vaccine in a Nationwide Mass Vaccination Setting
- (2021) Noa Dagan et al. NEW ENGLAND JOURNAL OF MEDICINE
- Antibody Responses in Seropositive Persons after a Single Dose of SARS-CoV-2 mRNA Vaccine
- (2021) Florian Krammer et al. NEW ENGLAND JOURNAL OF MEDICINE
- Kinetics and correlates of the neutralizing antibody response to SARS-CoV-2 infection in humans
- (2021) Kanika Vanshylla et al. Cell Host & Microbe
- Heterologous prime-boost COVID-19 vaccination: initial reactogenicity data
- (2021) Robert H Shaw et al. LANCET
- Thrombosis and Thrombocytopenia after ChAdOx1 nCoV-19 Vaccination
- (2021) Nina H. Schultz et al. NEW ENGLAND JOURNAL OF MEDICINE
- Thrombotic Thrombocytopenia after ChAdOx1 nCov-19 Vaccination
- (2021) Andreas Greinacher et al. NEW ENGLAND JOURNAL OF MEDICINE
- Heterologous vaccination regimens with self-amplifying RNA and adenoviral COVID vaccines induce robust immune responses in mice
- (2021) Alexandra J. Spencer et al. Nature Communications
- Interim Estimates of Vaccine Effectiveness of BNT162b2 and mRNA-1273 COVID-19 Vaccines in Preventing SARS-CoV-2 Infection Among Health Care Personnel, First Responders, and Other Essential and Frontline Workers — Eight U.S. Locations, December 2020–March 2021
- (2021) Mark G. Thompson et al. MMWR-MORBIDITY AND MORTALITY WEEKLY REPORT
- Immunogenicity and reactogenicity of BNT162b2 booster in ChAdOx1-S-primed participants (CombiVacS): a multicentre, open-label, randomised, controlled, phase 2 trial
- (2021) Alberto M Borobia et al. LANCET
- Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: a preliminary report of a phase 1/2, single-blind, randomised controlled trial
- (2020) Pedro M Folegatti et al. LANCET
- Safety and Immunogenicity of Two RNA-Based Covid-19 Vaccine Candidates
- (2020) Edward E. Walsh et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and immunogenicity of ChAdOx1 nCoV-19 vaccine administered in a prime-boost regimen in young and old adults (COV002): a single-blind, randomised, controlled, phase 2/3 trial
- (2020) Maheshi N Ramasamy et al. LANCET
- Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
- (2020) Fernando P. Polack et al. NEW ENGLAND JOURNAL OF MEDICINE
- Safety and immunogenicity of a two-dose heterologous Ad26.ZEBOV and MVA-BN-Filo Ebola vaccine regimen in adults in Europe (EBOVAC2): a randomised, observer-blind, participant-blind, placebo-controlled, phase 2 trial
- (2020) Andrew J Pollard et al. LANCET INFECTIOUS DISEASES
- Heterologous prime–boost vaccination
- (2009) Shan Lu CURRENT OPINION IN IMMUNOLOGY
Discover Peeref hubs
Discuss science. Find collaborators. Network.
Join a conversationAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started